26 results
8-K
EX-99.1
ZLAB
Zai Lab Limited
27 Sep 22
Entry into a Material Definitive Agreement
8:08am
of cancer death in women in China and globally. An estimated 110,000 new cases of cervical cancer occur annually in China1. Treatment options are limited
8-K
EX-99.1
oxhds
6 Jan 22
Zai Lab Announces NDA Acceptance of
7:44am
8-K
EX-99.1
0punlsqxnin
3 Dec 21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
7:45am
DEF 14A
kdr8s
30 Apr 21
Definitive proxy
4:02pm
424B5
2pclkw
21 Apr 21
Prospectus supplement for primary offering
4:45pm
424B5
ucdtdgtdf816 vsgnsjg
19 Apr 21
Prospectus supplement for primary offering
4:57pm
PRE 14A
1ksy7gtk81ez942s2
14 Apr 21
Preliminary proxy
4:00pm
10-K
l8lhp9kan89va
1 Mar 21
Annual report
12:00am
6-K
EX-99.1
js74 vz5u9d
29 Dec 20
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List
7:30am
6-K
EX-99.1
ng1wdly36fzl8pw1k35d
11 Sep 20
Zai Lab Limited Supplemental and Updated Disclosures
8:09am
6-K
EX-99.1
fj3bb02 80nnf7v52s
10 Sep 20
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China
7:35am
6-K
EX-99.1
4rne96is8ylyy6zrmzvu
16 Mar 20
Zai Lab Announces Acceptance of sNDA Submission of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in China by the NMPA
7:39am
424B2
6ou5ke696np
24 Jan 20
Prospectus for primary offering
7:24am
424B5
tyunaef6
21 Jan 20
Prospectus supplement for primary offering
5:31pm
6-K
EX-99.1
k7xy4in1a
27 Dec 19
Zai Lab Announces NMPA Approval of ZEJULA® (Niraparib) in China as Maintenance Therapy for Patients with Recurrent Ovarian Cancer
7:51am